1226860-98-5

Basic information

• Product Name: 1-[2-({6-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridin-3-yl}amino)ethyl]piperidin-4-ol
• Synonyms: 1-[2-({6-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridin-3-yl}amino)ethyl]piperidin-4-ol
• CAS NO: 1226860-98-5
• Molecular Weight: 543.549
• Mol File: 1226860-98-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[2-({6-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridin-3-yl}amino)ethyl]piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2-({6-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridin-3-yl}amino)ethyl]piperidin-4-ol(1226860-98-5)
• EPA Substance Registry System: 1-[2-({6-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridin-3-yl}amino)ethyl]piperidin-4-ol(1226860-98-5)

Safety Data

• Hazardous Substances Data: 1226860-98-5(Hazardous Substances Data)

Upstream product

• 31181-83-6 2-(hydroxymethyl)-5-iodopyridine 
• 116195-81-4 2,5-di-iodopyridine 
• 1085453-46-8 5-(5-methyl-1H-pyrazol-3-yl)-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole 
• 1225380-30-2 2-(chloromethyl)-5-iodopyridine 
• 402-61-9 5-methyl-1H-pyrazole-3-carboxylic acid 
• 1225380-63-1 5-iodo-2-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridine 
• 129999-60-6 N-(2-aminoethyl)-4-hydroxypiperidine 

Relevant articles and documents

Aryl compounds with aminoalkyl substituents and their use

The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.